<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291915</url>
  </required_header>
  <id_info>
    <org_study_id>GUEPARD-GERCER 2122</org_study_id>
    <nct_id>NCT00291915</nct_id>
  </id_info>
  <brief_title>Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis</brief_title>
  <official_title>Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goupe d'Etudes et de Recherche Clinique En Rhumatologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goupe d'Etudes et de Recherche Clinique En Rhumatologie</source>
  <brief_summary>
    <textblock>
      Evaluation of two treatment modalities in early potentially severe early arthritis (
      Methotrexate alone or in combination with adalimumab)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients: early ( less than 6 months), active ( DAS&gt;5.2),potentially severe ( Leiden score&gt;6)
      Study design:12 months, prospective , randomized, open Study treatments: Methotrexate at a
      weekly dose of 0.3mg/kilo alone or in combination with adalimumab 40 mg every the other week
      Outcome measures: DAS over the 12 months
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2004</start_date>
  <completion_date>March 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity Score</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>-Radiological score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Functional impairment ( HAQ)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Pain (VAS)</measure>
  </secondary_outcome>
  <enrollment>80</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Early Active Potentially severe arthritis

        Exclusion Criteria:

          -  contra indication of methotrexate or anti TNF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxime DOUGADOS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Cochin Paris FRance</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maxime r DOUGADOS, MD</last_name>
    <phone>00 33 1 58 41 25 62</phone>
    <email>maxime.dougados@cch.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin SOUBRIER, MD</last_name>
    <phone>00 33 6 81 74 78 85</phone>
    <email>msoubrier@chu-clermontferrand.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime DOUGADOS, md</last_name>
      <phone>00 33 1 58 41 25 62</phone>
      <email>maxime.dougados@cch.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Martin SOUBRIER, MD</last_name>
      <phone>00 33 6 81 74 78 85</phone>
      <email>msoubrier@chu-clermond ferrand.fr</email>
    </contact_backup>
    <investigator>
      <last_name>maxime DOUGADOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin SOUBRIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard COMBE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean SIBILIA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier MEYER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier PUECHAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françis BERENBAUM, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier MARIETTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice FARDELLONE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>René Marc FLIPO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe GOUPILLE, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry SCHAEVERBEKE, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>C ZARNITSKY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2006</study_first_submitted>
  <study_first_submitted_qc>February 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2006</study_first_posted>
  <last_update_submitted>February 14, 2006</last_update_submitted>
  <last_update_submitted_qc>February 14, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2006</last_update_posted>
  <keyword>early arthritis, methotrexate, adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

